Rosiglitazone and pioglitazone: two new thiazolidinediones
Open Access
- 1 July 2000
- journal article
- leader
- Published by Wiley in Practical Diabetes International
- Vol. 17 (5) , 135-137
- https://doi.org/10.1002/1528-252x(200007/08)17:5<135::aid-pdi92>3.0.co;2-o
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes MellitusJAMA, 2000
- Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetesDiabetologia, 2000
- Hepatic Failure in a Patient Taking RosiglitazoneAnnals of Internal Medicine, 2000
- Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patientsDiabetic Medicine, 2000
- Metformin: a useful adjunct to insulin therapy?Diabetic Medicine, 2000
- Insulin resistance and antidiabetic drugsBiochemical Pharmacology, 1999
- Cardiovascular risk in type 2 diabetesDiabetes, Obesity and Metabolism, 1999
- Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled studyDiabetes, Obesity and Metabolism, 1999
- Thiazolidinediones: a new class of antidiabetic drugsDiabetic Medicine, 1999
- Pathophysiology of insulin resistance in human diseasePhysiological Reviews, 1995